Skip to main content
Quest Diagnostics

Among Those With Normoglycemia, Insulin Resistance Risk Score (IRRS) Elevation is Observed up to 3 Years Prior to Diagnosis of Diabetes or Prediabetes

ADA 2025

American Diabetes Association

Chicago, IL, June 20-23 , 2025

Poster presentation: Among Those With Normoglycemia, Insulin Resistance Risk Score (IRRS) Elevation is Observed up to 3 Years Prior to Diagnosis of Diabetes or Prediabetes

Authors: Louie JZ, Shiffman D, Melander O, Abassi F, Meigs JB, and McPhaul MJ

Medical Specialty: Endocrinology, Cardiology, Cardiovascular disease, General Health and Wellness

Related content

Audio Podcast
Action From Insight: Tackling Insulin Resistance
Audio Podcast
The Insulin Resistance Revolution: The Key to Preventing Chronic Conditions
Publication
The relationship between insulin resistance and ion mobility lipoprotein fractions
Conference Presentation
Measures of Insulin Resistance (IR) Increase with Increasing BMI in a Population of Normoglycemic Working Adults
Test FAQ
CardioIQ® Insulin Resistance Panel with Score
On-Demand Webinar
Early identification of cardiometabolic disease: NAFLD/MASLD & NASH/MASH
Publication
Insulin Resistance Probability Score and Incident Cardiovascular Disease

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.